Effect of long-acting injectable antipsychotics on hospitalizations and global functioning in schizophrenia: a naturalistic mirror-image study

Effect of long-acting injectable antipsychotics on hospitalizations and global functioning in schizophrenia: a naturalistic mirror-image study

Background: Partial adherence to antipsychotics is the most common cause of relapses and rehospitalization in patients with schizophrenia (SZ), leading to higher health care costs and psychosocial disability. The use of long-acting injectable (LAI) antipsychotics may improve therapeutic continuity a...

Full description

Bibliographic Details
Main Authors:	Cristiana Montemagni, Elisa Del Favero, Elena Cocuzza, Flavio Vischia, Paola Rocca
Format:	Article
Language:	English
Published:	SAGE Publishing 2022-10-01
Series:	Therapeutic Advances in Psychopharmacology
Online Access:	https://doi.org/10.1177/20451253221122526

Similar Items

Second Generation Long-Acting Injectable Antipsychotics in Schizophrenia: The Patient’s Subjective Quality of Life, Well-Being, and Satisfaction
by: Claudio Brasso, et al.
Published: (2023-11-01)

The Use of Long-Acting Injectable Antipsychotic Therapy for Schizophrenia
by: Jason Jiang, et al.
Published: (2018-09-01)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
by: John M. Kane, et al.
Published: (2023-03-01)

Switching Antipsychotic Medications in People with Schizophrenia: A 4-Year Naturalistic Study
by: Giammarco Cascino, et al.
Published: (2022-10-01)

Expert Consensus on Long-acting Injectable Antipsychotic in the Treatment of Schizophrenia in Community
by: Chinese Schizophrenia Coordination Group, Chinese Society of Psychiatry, Chinese Society of General Practice
Published: (2022-10-01)

Analysis of Oral versus Long-acting Injectable Antipsychotics in the Maintenance of Schizophrenia
by: O. Vasiliu
Published: (2022-06-01)

Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia
by: Riboldi I, et al.
Published: (2022-12-01)

Effect of Transition to Long-acting Injectable Antipsychotic Treatment on Care Burden in Schizophrenia
by: Elif Özcan Tozoğlu, et al.
Published: (2021-12-01)

The combination of long-acting injectable antipsychotics, a new key in resistant schizophrenia
by: M.F. Tascón Guerra, et al.
Published: (2022-06-01)

The Effect of Longer Dosing Intervals for Long-Acting Injectable Antipsychotics on Outcomes in Schizophrenia
by: Milz R, et al.
Published: (2023-03-01)

Swithching Antipsychotic Medications in People with Schizophrenia: A 4-Year Naturalistic Study
by: R. Ceres, et al.
Published: (2023-03-01)

Long-acting injectable antipsychotics for the treatment of bipolar disorder: evidence from mirror-image studies
by: Francesco Bartoli, et al.
Published: (2023-03-01)

The effect of long-acting injectable antipsychotics on QRISK3 in patients with bipolar disorder and schizophrenia
by: V. Erbasan, et al.
Published: (2023-03-01)

Long-Acting Injectable Antipsychotic Treatment for Schizophrenia in Asian Population: A Scoping Review
by: Ma N, et al.
Published: (2023-09-01)

Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians
by: Citrome L, et al.
Published: (2022-01-01)

Maintenance antipsychotic medication patterns in outpatient schizophrenia patients: a naturalistic cohort study.
by: Burns, T, et al.
Published: (2006)

Benefits of Community-based Treatment for Patients with Schizophrenia: Based on Long-acting Injectable Antipsychotic Agents
by: Schizophrenia Coordination Group, Chinese Society of Psychiatry, Chinese Society of General Practice, LI Qian, SI Tianmei
Published: (2024-03-01)

Preliminary results of a network meta-analysis on the efficacy of long-acting injectable antipsychotics in schizophrenia
by: R. Medrano, et al.
Published: (2021-04-01)

Conceptual disorganization as a mediating variable between visual learning and metacognition in schizophrenia
by: Cristiana Montemagni, et al.
Published: (2023-12-01)

Atypical Antipsychotics in the Treatment of Depressive and Psychotic Symptoms in Patients with Chronic Schizophrenia: A Naturalistic Study
by: Marco Innamorati, et al.
Published: (2013-01-01)

The relative contributions of insight and neurocognition to intrinsic motivation in schizophrenia
by: Claudio Brasso, et al.
Published: (2022-03-01)

Schizophrenia long-acting antipsychotics initiation index (SLAAII)
by: P. Ifteni, et al.
Published: (2021-04-01)

The Management of Prodromal Symptoms of Bipolar Disorder: Available Options and Future Perspectives
by: Elisa Del Favero, et al.
Published: (2021-05-01)

Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland
by: Stephan Reymann, et al.
Published: (2022-03-01)

Long acting injectable antipsychotics – Where are we?
by: Phani Prasant Mulakaluri
Published: (2015-01-01)

Pharmacological Treatment for Social Cognition: Current Evidence
by: Cecilia Riccardi, et al.
Published: (2021-07-01)

The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia
by: Christopher Evernden, BSc, BScPharm, ACPR, et al.
Published: (2021-09-01)

Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review
by: Kunal Maini, et al.
Published: (2021-07-01)

Benzodiazepines and Mood Stabilizers in Schizophrenia Patients Treated with Oral versus Long-Acting Injectable Antipsychotics—An Observational Study
by: Ana Aliana Miron, et al.
Published: (2023-01-01)

Long-acting injectable antipsychotics during pregnancy: An update
by: A. Paraschakis, et al.
Published: (2021-04-01)

Long-Acting Injectable Second-Generation Antipsychotics in Seriously Ill Patients with Schizophrenia: Doses, Plasma Levels, and Treatment Outcomes
by: Juan José Fernández-Miranda, et al.
Published: (2024-01-01)

Long‐acting injectable antipsychotics as maintenance therapy for schizophrenia during the COVID‐19 pandemic: A micro‐narrative review
by: Yoshiyo Oguchi, et al.
Published: (2024-03-01)

Effectiveness of Long-Acting Injectable Antipsychotics in Schizophrenia: A Literature Review and Bayesian Meta-Analysis Informing Economic Considerations
by: Orietta Zaniolo, et al.
Published: (2019-02-01)

Effect of long-acting antipsychotic treatment on psychiatric hospitalization rate in early psychosis patients: a naturalistic study
by: Raúl Sancho-Echeverria, et al.
Published: (2024-04-01)

Knowledge about antipsychotic long-acting injections: bridging that gap
by: Burns, T
Published: (2009)

Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics
by: Francisco José Toja-Camba, et al.
Published: (2021-06-01)

The use of long-acting injectable antipsychotics in an acute psychiatric unit
by: G. Ortega-Hernández, et al.
Published: (2023-03-01)

Use of Long-Acting Injectable Antipsychotics in a Clinical Sample of Community-Dwelling Patients with Schizophrenia-Spectrum Disorders in Rural Greece
by: Vaios Peritogiannis, et al.
Published: (2023-03-01)

Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM
by: Litman R, et al.
Published: (2023-01-01)

Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review
by: Taro Kishi, et al.
Published: (2021-09-01)